Autopsy report · NCT01797965

Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019

“Study terminated because of differences in the participant population under study compared with indicated Zinbryta use in most countries.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 5 years 7 months before it stopped.
• 1,501 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Biogen

Sponsor type

Industry

Conditions

Relapsing-Remitting Multiple Sclerosis; Multiple Sclerosis

Interventions

BIIB019 (Daclizumab)

Participants

1,501

Sites

222

Countries

Argentina, Australia, Brazil, Canada, Czechia, Denmark, France, Georgia, Germany, Greece, Hungary, India and more

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.